Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

lobaplatin (D19466)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AEterna Zentaris

Drug class:

Alkylating agent

Related drugs:

‹

›

HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	capecitabine + D19466 Sensitive: C3 – Early Trials capecitabine + D19466 Sensitive : C3	capecitabine + D19466 Sensitive: C3 – Early Trials capecitabine + D19466 Sensitive : C3
HRD + BRCA wild-type	Triple Negative Breast Cancer	HRD + BRCA wild-type	Triple Negative Breast Cancer	D19466 Sensitive: C3 – Early Trials D19466 Sensitive : C3	D19466 Sensitive: C3 – Early Trials D19466 Sensitive : C3
HRD	Triple Negative Breast Cancer	HRD	Triple Negative Breast Cancer	D19466 Sensitive: C3 – Early Trials D19466 Sensitive : C3	D19466 Sensitive: C3 – Early Trials D19466 Sensitive : C3
INPP4B overexpression	Hepatocellular Cancer	INPP4B overexpression	Hepatocellular Cancer	D19466 Sensitive: D – Preclinical D19466 Sensitive : D	D19466 Sensitive: D – Preclinical D19466 Sensitive : D